



Treatment of Stage IV Melanoma

Melanoma Vaccine

Description of Technology

This technology is a novel vaccine treatment for stage IV (late stage) melanoma. The vaccine has been shown to reduce melanoma in approximately 20% of patients tested and slow down the rate of progression in more than 80% of patients tested. Compared to current therapies, this treatment is a more efficacious method of combating this terminal disease. Furthermore, the side effects associated with the most common therapies of stage IV melanoma (in particular, chemotherapy) are not observed in patients treated with this vaccine, resulting in more effective palliative care.

Commercial Applications

Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma, the most aggressive form of skin cancer, accounts for approximately 4% of skin cancer cases but causes about 79% of skin cancer-related deaths. This vaccine for stage IV melanoma is currently in phase II clinical trials.

Patent Status

An international patent application covering the technology has been filed.

Summary

University of Adelaide Researchers have developed a vaccine treatment for late stage melanoma. The treatment is more efficacious than current treatments and does not have the side effects associated with most therapies.

Key People

A/Prof Brendon Coventry
Discipline of Surgery

Partnership Opportunities

This vaccine for stage IV melanoma is currently in phase II clinical trials and we are seeking to licence to partners interested in the development of cancer therapies and/or vaccine strategies, for the continued development of this technology as a human therapeutic for stage IV melanoma.



THE UNIVERSITY
OF ADELAIDE
AUSTRALIA

Contact:

Dr Justin Dibbens

**Commercial Development
Adelaide Research & Innovation**

GPO Box 149, Rundle Mall

Adelaide SA 5000 Australia

Tel: +61 8 8303 5020

Fax: +61 8 8303 4355

Email: justin.dibbens@adelaide.edu.au